1.6mn pharma funding for nephrotoxicity model | Mimetas

1.6mn pharma funding for nephrotoxicity model

1.6mn pharma funding for nephrotoxicity model

1.6 million USD pharma funding for kidney-on-a-chip nephrotoxicity model

MIMETAS, in a consortium with Radboudumc (Nijmegen) and FHNW (Basel), has received 1.6 million USD funding for development of a kidney-on-a-chip for toxicological applications. A panel of experts from GlaxoSmithKline, Pfizer, Roche, NC3Rs and renowned academic institutions selected MIMETAS’ solution from a strong line-up of competing technologies.

The funding is awarded in the context of the NephroTube Crack-it Challenge to support development of a microfluidic renal model. In collaboration with the Radboudumc Pharmacology-Toxicology Department and the Swiss FHNW, MIMETAS will use the funds to develop a high-throughput kidney-on-a-chip model by combining its OrganoPlate® 3D-culturing technology with the human renal cell line ciPTEC™, analyzed and validated in three separate sites. The resulting model will be used to detect renal tubular injury observed in drug-induced nephrotoxicity. The model’s early prediction of nephrotoxicity will help to reduce animal experiments.

The Crack-it Challenge is organised by the UK-based National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs). In December 2013, MIMETAS and her partners received 160.000 dollar funding to deliver a successful proof-of-concept.